Blood, 1 January 2002, Vol. 99, No. 1, pp. 384-386
BRIEF REPORT
Liposomal amphotericin B (AmBisome) compared with amphotericin
B ± FMLP induces significantly less in vitro
neutrophil aggregation with granulocyte-colony-stimulating
factor/dexamethasone-mobilized allogeneic donor
neutrophils
Maria Luisa Sulis,
Carmella Van de Ven,
Theresa Henderson,
Lauren Anderson, and
Mitchell S. Cairo
From the Department of Pediatrics, Children's Hospital
of New York, Columbia University, New York, NY; and the Lombardi Cancer
Center, Georgetown University, Washington, DC.
Concomitant use of allogeneic donor granulocyte transfusions and
amphotericin B in febrile neutropenic recipients may be limited by the
increased incidence of respiratory distress. In vitro effects of
amphotericin B and AmBisome were compared on polymorphonuclear leukocyte (PMN) aggregation from PMNs isolated from
granulocyte-colony-stimulating factor (G-CSF)/dexamethasone-mobilized
allogeneic donors. Six allogeneic donors were mobilized with G-CSF (600 µg subcutaneously) and dexamethasone (8 mg orally) 12 hours
before leukopheresis. AmBisome was associated with significantly less
PMN aggregation (100 µM [µg/mL]) (0.33% ± 0.33% vs
54.33% ± 5.82%; P < .001) than amphotericin B. Furthermore, with the addition of the PMN agonist, FMLP, AmBisome was
also associated with significantly less aggregation (100 µM
[µg/mL]) (18.67% ± 1.45% vs 54.67% ± 2.4%;
P < .001). In summary, these studies demonstrate that
liposomal amphotericin is associated with significantly less in vitro
PMN aggregation than amphotericin B and could possibly be administered
concomitantly with mobilized allogeneic PMN infusions.
